The writer muses: "Ramadan asks us to practice restraint. But somewhere along the way, we started asking everyone else to practice it, too." ...

Amphenol maintains a Buy rating with a revised target price of $155, implying 17.7% upside driven by robust Q4 and full-year 2025 results. Click here to read more macro analysis here.

Following several Safaricom M-PESA app users who have voiced their frustrations with the platform, including difficulty viewing recent transactions, Safaricom has shared steps to fix the glitch. From ...

Lucas Downey is the co-founder of MoneyFlows, and an Investopedia Academy instructor. Andy Smith is a Certified Financial Planner (CFP®), licensed realtor and educator with over 35 years of diverse ...

Learn about unlisted securities: a financial instrument traded over-the-counter due to unmet formal exchange listing requirements, along with their types and risks.

Europe needs to roll up its sleeves, or it risks losing its last bit of independence to US-controlled payment schemes. As the first EU instant payment system, WERO aims to become Europe’s ticket to ...

After six months tracing where personal data actually travels post-consent, what emerged is a global supply chain ...

Victims lost $16.6 billion to cybercrime scams in 2024, but now the Marion County Sheriff's Office is recovering money for some of those victims.

Good morning, Nina Lindholm here with the Europe Wire from the London newsroom. While global Q4 private equity and venture capital deal volume yielded the weakest finish in the last five years, ...

Suit says woman has anxiety and obsessive compulsive disorder. Lawsuit wants academic sanctions lifted while the case proceeds. A student is suing the University of Michigan, claiming it wrongly ...

MINNEAPOLIS — Editor's note: The video above first aired in February 2025. A Minnesota Appeals Court judge upheld the expulsion of a University of Minnesota Ph.D. student for his alleged use of ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine programs. The tech, called Matrix-M, is designed to trigger an immune ...